好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Thalamic MRI Markers of Disability in a Large Real-world Multiple Sclerosis Cohort
Multiple Sclerosis
P8 - Poster Session 8 (11:45 AM-12:45 PM)
19-006
To assess MRI and demographic correlates of physical disability, measured by the Patient-Determined Disease Steps (PDDS), in a large real-world MS cohort.

Multiple sclerosis (MS) is a chronic demyelinating disease in which thalamic demyelination and degeneration contribute to neurological disability. We hypothesized that clinical symptom severity can be predicted by quantitative MRI measure of thalamic integrity.

We used T1w MPRAGE and T2w TSE acquired on Siemens 3T systems in the Mellen Center Clinical Practice Registry, segmented using FreeSurfer (v7.3.2) SynthSeg, and calculated thalamic volume and T1w/T2w ratio with established scaling methods. T2 lesion volume was calculated using deep learning algorithm. Extracted data were analyzed using a cumulative link mixed-effects model with random intercepts to predict ordinal PDDS categories (Low = 0–2, Mid = 3–4, High = 5–8). Analyses included patients with ≥3 longitudinal visits and minimum transient PDDS ≥1. Predictors included normalized thalamic T1w/T2w ratio, T2 lesion volume (T2LV), mean thalamic volume, age, sex, and disease duration.

Among 717 subjects (2,827 MRI–clinical pairs; 26.6% male; mean age 48.4 ± 10.6 and disease duration 15.5 ± 10.2 years), greater T2LV was significantly associated with worse PDDS (OR = 1.82, p < 0.001). Lower thalamic volume predicted greater disability (OR = 0.67, p = 0.038). The thalamic T1w/T2w ratio showed a positive, nonsignificant trend toward higher PDDS (OR = 1.22, p = 0.08). Age (OR = 1.09/year, p < 0.001) and disease duration (OR = 1.04/year, p = 0.009) were significant covariates; sex was not (p = 0.45).

In this large cohort, MRI-derived metrics of injury were robust correlates of disability. Thalamic atrophy and T2 lesion burden independently predicted higher PDDS. T1w/T2w was not associated with disability similar to prior findings. Substantial between-subject variability underscores disability heterogeneity and supports subject-specific modeling with future work extending this framework to additional longitudinal functional/cognitive measures.

Authors/Disclosures
Andrew Lamade, MD, PhD (Cleveland Clinic Foundation)
PRESENTER
Dr. Lamade has nothing to disclose.
Kunio Nakamura, PhD (Cleveland Clinic) Dr. Nakamura has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for INmune Bio. The institution of Dr. Nakamura has received research support from Biogen. The institution of Dr. Nakamura has received research support from PCORI. The institution of Dr. Nakamura has received research support from NIH. The institution of Dr. Nakamura has received research support from Genzyme. The institution of Dr. Nakamura has received research support from NIH. The institution of Dr. Nakamura has received research support from Genzyme. The institution of Dr. Nakamura has received research support from Novartis. The institution of Dr. Nakamura has received research support from DOD. Dr. Nakamura has received intellectual property interests from a discovery or technology relating to health care.
Daniel Ontaneda, MD, PhD, FAAN (Cleveland Clinic) Dr. Ontaneda has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Dr. Ontaneda has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Genentech/Roche. Dr. Ontaneda has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen Idec. Dr. Ontaneda has received personal compensation in the range of $500-$4,999 for serving as a Consultant for BMS. Dr. Ontaneda has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sanofi. The institution of Dr. Ontaneda has received research support from NIH. The institution of Dr. Ontaneda has received research support from PCORI. The institution of Dr. Ontaneda has received research support from NMSS. The institution of Dr. Ontaneda has received research support from Genetech.